Search results for "Blood coagulation"

showing 10 items of 154 documents

Chronic thromboembolic pulmonary hypertension from the perspective of patients with pulmonary embolism

2018

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but feared long-term complication of acute pulmonary embolism (PE), although CTEPH may occur in patients with no history of symptomatic venous thromboembolism. It represents the most severe presentation of the so-called 'post-PE syndrome', a phenomenon of permanent functional limitations after PE caused by deconditioning after PE or ventilatory or circulatory impairment as a result of unresolved pulmonary artery thrombi. Because the post-PE syndrome may occur in up to 50% of PE survivors, and CTEPH tends to have an insidious and non-specific clinical presentation, CTEPH is often not diagnosed or diagnosed after a very long dela…

medicine.medical_specialtyHypertension Pulmonarymedicine.medical_treatmentHemodynamicsEndarterectomyPulmonary Artery030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsAngioplastyInternal medicinemedicine.arterymedicineHumansArterial PressureBlood CoagulationAntihypertensive Agentsbusiness.industryAnticoagulantsHematologymedicine.diseasePulmonary hypertensionPulmonary embolismTreatment Outcomemedicine.anatomical_structure030228 respiratory systemChronic DiseaseCirculatory systemPulmonary arteryCardiologyVascular resistancePulmonary EmbolismbusinessComplicationAngioplasty BalloonJournal of Thrombosis and Haemostasis
researchProduct

Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats.

2013

Substantial improvements in the safety of blood and plasma products for the management of bleeding disorders have been achieved in recent decades. This has led some clinicians to believe that the infectious threat is over and that inhibitor formation is the foremost complication of hemophilia therapy. On the contrary, elimination of all microbes from blood is difficult, potentially impossible, and there are always threats from emerging pathogens. The risk of infection transmission is also increasing due to greater exposure to products, increasing prophylaxis and high-dose regimens for immune tolerance, and longevity of hemophilia patients. Current products can be considered "reasonably safe…

medicine.medical_specialtyLong term treatmentContext (language use)Hemophilia AInfectionsEmerging infectionsSAFERHumans; Blood Coagulation Disorders; Hemophilia A; Blood Transfusion; InfectionmedicineHumansBlood TransfusionIntensive care medicinePathogenTransmission (medicine)business.industryRisk of infectionTransfusion ReactionHematologyBlood Coagulation Disordersmedicine.diseaseSettore MED/07 - Microbiologia e Microbiologia ClinicaThrombosisSurgeryHemostasisPlasma productsBlood safetyCardiology and Cardiovascular MedicinebusinessInfectionSeminars in thrombosis and hemostasis
researchProduct

Benign intracranial hypertension associated to blood coagulation derangements

2006

Abstract Background Benign Intracranial Hypertension (BIH) may be caused, at least in part, by intracranial sinus thrombosis. Thrombosis is normally due to derangements in blood coagulation cascade which may predispose to abnormal clotting activation or deficiency in natural inhibitors' control. The aim of the study is to examine the strength of the association between risk factors for thrombosis and BIH. Patients and methods The incidence of prothrombotic abnormalities among a randomly investigated cohort of 17 patients with BIH, was compared with 51 healthy subjects matched for sex, age, body mass index, height and social background. Results The number of subjects with protein C deficienc…

medicine.medical_specialtyPathologymedicine.medical_treatmentGastroenterologysymbols.namesakeProtein C deficiencyIntracranial hypertension blood coagulation fibrinolysisInternal medicineFibrinolysismedicineFisher's exact testAngiologyHematologybiologylcsh:RC633-647.5business.industrylcsh:Diseases of the blood and blood-forming organsHematologymedicine.diseaseThrombosisMethylenetetrahydrofolate reductasesymbolsbiology.proteinOriginal Clinical InvestigationbusinessBody mass index
researchProduct

Factores de predicción de dosificación inadecuada de rivaroxabán utilizando la ecuación de CKD-EPI

2021

Yes

medicine.medical_specialtyPatientsCKD-EPI:Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Coagulation Disorders [Medical Subject Headings]Dosislcsh:RC870-923:Anatomy::Cardiovascular System::Blood Vessels::Arteries::Aorta [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]DosageRivaroxabanRivaroxabánmedicineRenal insufficiency chronicInsuficiencia renal crónicaGynecology:Diseases::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency Chronic [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Observational Study as Topic [Medical Subject Headings]business.industry:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Dosage Calculations [Medical Subject Headings]lcsh:Diseases of the genitourinary system. Urology:Persons::Persons::Patients [Medical Subject Headings]NephrologyPacientesDosificaciónbusiness:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Prescriptions [Medical Subject Headings]Nefrología
researchProduct

c.451dupT in KLKB1 is common in Nigerians, confirming a higher prevalence of severe prekallikrein deficiency in Africans compared to Europeans

2020

Essentials Prekallikrein (PK) deficiency is a recessive trait with isolated aPTT prolongation. KLKB1 c.451dupT is common in Nigerians (7/600 alleles) and absent in a European group (0/600). To date, all genotyped PK-deficient patients of African ancestry were homozygous for 451dupT. Diagnostics of isolated aPTT prolongation in African descendants should include PK testing. ABSTRACT: Background Severe prekallikrein deficiency (PK deficiency) is an autosomal-recessive condition thought to be very rare. Recently we reported that the previously unnoticed variant c.451dupT, p.Ser151Phefs*34 in KLKB1, which is listed in databases aggregating genome data, causes PK deficiency and is common in Afri…

medicine.medical_specialtyPopulationNigeria030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineEpidemiologyPrevalenceHumansMedicineAlleleeducationAllele frequencyBlood coagulation testeducation.field_of_studymedicine.diagnostic_testbusiness.industryNigeriansPrekallikreinPrekallikreinHematologyBlood Coagulation DisordersKallikreinsbusinessPartial thromboplastin timeJournal of Thrombosis and Haemostasis
researchProduct

A score model for the continuous grading of early allograft dysfunction severity

2014

Early allograft dysfunction (EAD) dramatically influences graft and patient outcomes. A lack of consensus on an EAD definition hinders comparisons of liver transplant outcomes and management of recipients among and within centers. We sought to develop a model for the quantitative assessment of early allograft function [Model for Early Allograft Function Scoring (MEAF)] after transplantation. A retrospective study including 1026 consecutive liver transplants was performed for MEAF score development. Multivariate data analysis was used to select a small number of postoperative variables that adequately describe EAD. Then, the distribution of these variables was mathematically modeled to assig…

medicine.medical_specialtyTime Factorsmedicine.medical_treatmentLiver transplantationModels BiologicalSeverity of Illness IndexDecision Support TechniquesLiver diseasePredictive Value of TestsRisk FactorsInternal medicineSeverity of illnessmedicineHumansInternational Normalized RatioBlood CoagulationProportional Hazards ModelsRetrospective StudiesPrincipal Component AnalysisTransplantationHepatologyProportional hazards modelbusiness.industryGraft SurvivalReproducibility of ResultsAlanine TransaminaseBayes TheoremBilirubinRetrospective cohort studyClinical Enzyme Testsmedicine.diseaseLiver TransplantationSurgeryTransplantationTreatment OutcomeNonlinear DynamicsPredictive value of testsMultivariate AnalysisSurgeryLiver functionPrimary Graft DysfunctionbusinessBiomarkersLiver Transplantation
researchProduct

Interaction between C1-INA, coagulation, fibrinolysis and kinin system in hereditary angioneurotic edema (HANE) and urticaria.

1984

The C1-inactivator plays an important role not only in the initial phases of the complement system, but also in those of the coagulation, fibrinolysis and kinin systems. The present study was concerned with the reciprocal influence of decreased C1-inactivator levels in patients with hereditary angioneurotic edema (HANE, HAE). In 13 HANE-I patients there were significantly increased levels of the coagulation factors XII, XI, V, of plasminogen and of alpha 2-antiplasmin, while the factors IX and VII were decreased. Conversely, it emerged that in patients with markedly raised prephase factor levels, angioneurotic edema occurred in the presence of normal or only slightly decreased C1-inactivato…

medicine.medical_specialtyUrticariaHereditary angioneurotic edemamedicine.medical_treatmentDermatologyKininsComplement C1 Inactivator Proteinschemistry.chemical_compoundInternal medicineEdemaFibrinolysismedicineHumansAngioedemaFactor XIIAngioedemaFactor VIIbusiness.industryFibrinolysisGeneral MedicineKininBlood Coagulation FactorsEndocrinologyCoagulationchemistryImmunologymedicine.symptombusinessArchives of dermatological research
researchProduct

Blood Coagulation and Thrombosis in Patients with Ovarian Malignancy

1997

SummaryOvarian cancer cells appear to be capable of both thrombin formation and induction of fibrin degradation which may be essential prerequisites for the development of deep vein thrombosis (DVT) as well as the spread of malignancy. To study further this coagulation – cancer interaction in 60 patients with untreated ovarian cancer of FIGO stage I-IV the incidence of DVT was recorded pre-operatively, postoperatively on day 1, 3, 5, 7, 10, before each of six cycles of Cisplati- num/Epirubicin/Cyclophosphamide chemotherapy, during follow-up and in the post-operative period of second look surgery. In addition, blood coagulation tests results were determined prospectively. Two patients were e…

medicine.medical_specialtymedicine.drug_classLow molecular weight heparinGastroenterologyPostoperative ComplicationsMedian follow-upThromboembolismInternal medicinemedicineHumansProspective Studiescardiovascular diseasesBlood CoagulationAgedBlood coagulation testOvarian NeoplasmsUnivariate analysisHeparinbusiness.industryAntithrombinAnticoagulantAnticoagulantsHematologyHeparinHeparin Low-Molecular-WeightMiddle AgedSurvival AnalysisSurgeryFemaleBlood Coagulation Testsbusinessmedicine.drugEpirubicinThrombosis and Haemostasis
researchProduct

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

2018

Abstract Background Prediction models for venous thromboembolism recurrence will likely be improved by adding levels of coagulation factors. Risk assessment is ideally performed during anticoagulant treatment, however, the influence of direct oral anticoagulants on coagulation factors is uncertain. Objective To assess the influence of rivaroxaban and apixaban on several coagulation factor levels. Methods In two crossover trials we assessed the influence of rivaroxaban and apixaban intake on factor (F)VIII, FXI and FXII‐activity and fibrinogen, von Willebrand factor (VWF:Ag), and d‐dimer levels. At three sessions with a washout period in between, blood was taken from 12 healthy male individu…

medicine.medical_specialtymedicine.drug_mechanism_of_actionFactor Xa Inhibitorapixabanfactor Xa inhibitors030204 cardiovascular system & hematologyTreatment resultsFibrinogenGastroenterology03 medical and health sciences0302 clinical medicineVon Willebrand factorInternal medicinecoagulantsMedicinerivaroxabanBlood coagulation testRivaroxabanbiologybusiness.industryBrief Reportblood coagulation testsrisk assessmentHematologyCoagulation030220 oncology & carcinogenesisbiology.proteinApixabanbusinessOriginal Articles: Thrombosismedicine.drug
researchProduct

Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants.

2018

BACKGROUND AND PURPOSE Whereas intravenous thrombolysis (IVT) is allowed for acute ischaemic stroke in patients on vitamin K antagonists with international normalized ratio ≤1.7, there are no similar recommendations for patients on direct oral anticoagulants (DOACs), notably due to the lack of coagulation tests to assess the therapeutic effects. Although the literature is scarce, consisting of small case series and retrospective studies, considering the frequency of this situation the French Vascular Neurology Society and the French Study Group on Haemostasis and Thrombosis have worked on a joint position paper to provide a practical position regarding the emergency management of ischaemic …

medicine.medical_specialtymedicine.medical_treatmentAdministration Oral030204 cardiovascular system & hematologyAntithrombinsDabigatranBrain Ischemia03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRivaroxabanAtrial FibrillationCoagulation testingMedicineHumansThrombolytic TherapyStrokeRetrospective StudiesProthrombin timeRivaroxabanmedicine.diagnostic_testbusiness.industryAnticoagulantsIdarucizumabThrombolysismedicine.diseaseDabigatranStrokeNeurologyEmergency medicineAdministration IntravenousNeurology (clinical)Blood Coagulation Testsbusiness030217 neurology & neurosurgeryPartial thromboplastin timemedicine.drugFactor Xa InhibitorsEuropean journal of neurology
researchProduct